Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert S Busch

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Postgraduate Medicine|June 29, 2017
Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetesRobert S Busch, Michael P Kane
The Annals of Pharmacotherapy|March 16, 2006
Drug-induced thyrotoxic periodic paralysisMichael P Kane, Robert S Busch
Current Diabetes Reviews|January 29, 2008
The utility of oral diabetes medications in type 2 diabetes of the youngMichael P Kane, Asim Abu-Baker, Robert S Busch
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2021
The Occurrence and Burden of Hypophosphatasia in an Ambulatory Care Endocrinology PracticeHugh B Quinn, Robert S Busch, Michael P Kane
Case Reports in Endocrinology|December 1, 2012
Spontaneous resolution of primary hyperparathyroidism in parathyroid adenomaSara J Micale, Michael P Kane, Robert S Busch
International Journal of Clinical Practice|October 19, 2017
Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trialsRobert S Busch, James Ruggles, Jenny Han, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
A real-world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672)Matthew D Stryker, Michael P Kane, Robert S Busch
Pharmacotherapy|September 28, 2007
Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infectionCatherine A Sheffield, Michael P Kane, Robert S Busch
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Substitution of pioglitazone for troglitazone in patients with type 2 diabetesMichael P Kane, Robert S Busch, Gary Bakst, et al.
Clinical Medicine Insights. Endocrinology and Diabetes|August 4, 2016
No Postoperative Adrenal Insufficiency in a Patient with Unilateral Cortisol-Secreting Adenomas Treated with Mifepristone Before SurgeryRachel M Saroka, Michael P Kane, Lawrence Robinson, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Postgraduate Medicine|June 29, 2017
Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetesRobert S Busch, Michael P Kane
The Annals of Pharmacotherapy|March 16, 2006
Drug-induced thyrotoxic periodic paralysisMichael P Kane, Robert S Busch
Current Diabetes Reviews|January 29, 2008
The utility of oral diabetes medications in type 2 diabetes of the youngMichael P Kane, Asim Abu-Baker, Robert S Busch
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2021
The Occurrence and Burden of Hypophosphatasia in an Ambulatory Care Endocrinology PracticeHugh B Quinn, Robert S Busch, Michael P Kane
Case Reports in Endocrinology|December 1, 2012
Spontaneous resolution of primary hyperparathyroidism in parathyroid adenomaSara J Micale, Michael P Kane, Robert S Busch
International Journal of Clinical Practice|October 19, 2017
Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trialsRobert S Busch, James Ruggles, Jenny Han, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
A real-world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672)Matthew D Stryker, Michael P Kane, Robert S Busch
Pharmacotherapy|September 28, 2007
Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infectionCatherine A Sheffield, Michael P Kane, Robert S Busch
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Substitution of pioglitazone for troglitazone in patients with type 2 diabetesMichael P Kane, Robert S Busch, Gary Bakst, et al.
Clinical Medicine Insights. Endocrinology and Diabetes|August 4, 2016
No Postoperative Adrenal Insufficiency in a Patient with Unilateral Cortisol-Secreting Adenomas Treated with Mifepristone Before SurgeryRachel M Saroka, Michael P Kane, Lawrence Robinson, et al.
Pageof 3